A-836339 是一种口服有效的选择性 CB2 受体激动剂,对人和大鼠的 Ki 分别为 0.4 nM 和 0.8 nM,具有镇痛、胃保护、抗炎和抗氧化等多种作用,其通过激活背根神经节和脊髓中的 CB2 受体产生抗伤害和镇痛活性,也能通过抗炎(降低 TNF-α、IL-1β)和抗氧化机制(增强 CAT、SOD 活性,减少 H2O2)实现胃保护作用,放射性标记的 A-836339 可作为 CB2 特异性放射配体用于自显影和 PET 成像,并可用于炎症性疼痛、神经病理性疼痛、胃溃疡和脑缺血等研究。
产品编号: MS-E88761 纯度: 99.84% CAS No.: 959746-77-1 分子式: C16H26N2O2S 分子量: 310.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

A-836339 是一种口服有效的选择性 CB2 受体激动剂,对人和大鼠的 Ki 分别为 0.4 nM 和 0.8 nM,具有镇痛、胃保护、抗炎和抗氧化等多种作用,其通过激活背根神经节和脊髓中的 CB2 受体产生抗伤害和镇痛活性,也能通过抗炎(降低 TNF-α、IL-1β)和抗氧化机制(增强 CAT、SOD 活性,减少 H2O2)实现胃保护作用,放射性标记的 A-836339 可作为 CB2 特异性放射配体用于自显影和 PET 成像,并可用于炎症性疼痛、神经病理性疼痛、胃溃疡和脑缺血等研究。

生物实验数据

生物活性 A-836339 is an orally active and selective CB2 receptor agonist with Ki values of 0.4 nM for human and 0.8 nM for rat, exhibiting multiple effects including analgesia, gastric protection, anti-inflammation, and antioxidation; it produces antinociceptive and analgesic activity by activating CB2 receptors in the dorsal root ganglion and spinal cord, and also achieves gastric protection through anti-inflammatory (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing CAT and SOD activities and decreasing H2O2); radiolabeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging, and can be used for research on inflammatory pain, neuropathic pain, gastric ulcer, and cerebral ischemia.
体外研究
(In Vitro)

A-836339(20 µM;20分钟;脑切片)在 LPS 和 AMPA 注射后降低同侧半球中 [11C]A-836339 的结合。

体内研究
(In Vivo)

A-836339(0.3 µmol/kg;i.t.)通过作用于脊髓部位逆转神经病理性疼痛。
A-836339(0.3 µmol/kg;intra-DRG)通过作用于背根神经节部位逆转炎症性疼痛。
A-836339(0.3 µmol/kg;intra-DRG)通过作用于背根神经节部位逆转神经病理性疼痛。
A-836339(1-10 µmol/kg;IP)通过 CB2 受体作用逆转炎症性疼痛。
A-836339(3-30 µmol/kg;IP)通过激活 CB2 受体且无阿片类药物依赖性,在 CCI 模型中逆转神经病理性疼痛。
A-836339(1-5 mg/kg;口服)通过增强胃保护作用和逆转组织学损伤,降低乙醇(EtOH)诱导的小鼠胃溃疡模型中的溃疡指数和 ULI,同时降低 TNF-α 水平,并通过增加 CAT 和 SOD 活性以及减少 H2O2 水平来增强抗氧化防御机制。
A-836339(1-5 mg/kg;口服)在 NSAID 诱导的小鼠胃溃疡模型中降低溃疡指数和 ULI,增强 CAT 活性并减少 H2O2 水平,同时降低 TNF-α 水平。
A-836339(5 mg/kg;口服)在乙醇(EtOH)诱导的小鼠溃疡模型中,显示出胃组织中 CB2 受体和 COX-2 的共定位。

Animal Model: Sprague Dawley rats (male, 250-300 g); inflammatory model, induced by CFA injection
Dosage: 1 µmol/kg, 3 µmol/kg, 10 µmol/kg
Administration: IP
Result: Significantly reversed CFA-induced thermal hyperalgesia in a dose-dependent manner, with an ED50 of 1.8 µmol/kg. The effect was blocked by a CB2 antagonist but not a CB1 antagonist.
Animal Model: Sprague Dawley rats (male, 250-300 g); neuropathic model, induced by SNL
Dosage: 3 µmol/kg, 10 µmol/kg, 30 µmol/kg
Administration: IP
Result: Systemic A-836339 dose-dependently reversed SNL-induced mechanical allodynia (67% at 30 µmol/kg, ED50 14.5 µmol/kg). The effect was not blocked by naloxone.
Animal Model: Sprague Dawley rats (male, 250-300 g); neuropathic model, induced by CCI
Dosage: 3 µmol/kg, 10 µmol/kg, 30 µmol/kg
Administration: IP
Result: Systemic A-836339 attenuated CCI-induced mechanical allodynia (71% at 30 µmol/kg). The effect was blocked by a CB2 antagonist.
Animal Model: Sprague Dawley rats (male, 250-300 g); inflammatory model, induced by CFA injection
Dosage: 0.3 µmol/kg
Administration: Others (intra-DRG)
Result: Intra-DRG administration of A-836339 significantly reversed CFA-induced thermal hyperalgesia (65%).
Animal Model: Sprague Dawley rats (male, 250-300 g); inflammatory model, induced by CFA injection
Dosage: 0.3 µmol/kg
Administration: Others (i.t.)
Result: Intrathecal administration of A-836339 did not significantly reverse CFA-induced thermal hyperalgesia (14%).
Animal Model: Sprague Dawley rats (male, 250-300 g); inflammatory model, induced by CFA injection
Dosage: 0.2 µmol/kg, 0.6 µmol/kg
Administration: Others (i.paw)
Result: Ipsilateral intraplantar administration of A-836339 showed a weak effect (27% reversal at 0.6 µmol/kg), with similar effects observed on the contralateral paw.
Animal Model: Sprague Dawley rats (male, 250-300 g); neuropathic model, induced by SNL
Dosage: 0.3 µmol/kg
Administration: Others (intra-DRG)
Result: Intra-DRG administration of A-836339 significantly attenuated SNL-induced mechanical allodynia (45%).
Animal Model: Sprague Dawley rats (male, 250-300 g); neuropathic model, induced by SNL
Dosage: 0.3 µmol/kg
Administration: Others (i.t.)
Result: Intrathecal administration of A-836339 reversed SNL-induced mechanical allodynia (33%).
Animal Model: Balb/C mice (male, 21-23 g); EtOH-induced gastric ulcer model, induced by 80% EtOH
Dosage: 1 mg/kg, 3 mg/kg, 5 mg/kg
Administration: Oral
Result: Reduced ulcer index and ULI in a dose-dependent manner. Administration of the CB2 antagonist AM630 (1 mg/kg, i.p.) before A836339 (5 mg/kg, p.o.) significantly reversed its gastroprotective effect. Histological analysis showed reversed damage after A836339 administration. Reduced TNF-α levels compared to EtOH-treated group. Partial reversal of anti-inflammatory effect by AM630 (1 mg/kg, i.p.), though not statistically significant. IL-1β levels showed non-significant reduction. Increased catalase (CAT) and superoxide dismutase (SOD) activities in a dose-dependent manner. Reduced H2O2 levels, with the highest dose (5 mg/kg) showing statistical significance. Effects reversed by AM630 (1 mg/kg, i.p.).
Animal Model: Balb/C mice (male, 21-23 g); EtOH-induced gastric ulcer model, induced by 80% EtOH
Dosage: 5 mg/kg
Administration: Oral
Result: Co-localization of CB2 receptors and COX-2 in non-neuronal gastric tissue observed via immunohistochemistry (IHC).
Animal Model: Balb/C mice (male, 21-23 g); NSAID-induced gastric ulcer model, induced by diclofenac 30 mg/kg p.o.
Dosage: 1 mg/kg, 3 mg/kg, 5 mg/kg
Administration: Oral
Result: Reduced ulcer index and ULI in a dose-dependent manner, though differences were not statistically significant. Histological damage reversed by A836339 administration. CAT activity increased, H2O2 levels reduced. GSH levels decreased. Reduced TNF-α levels compared to NSAID-treated group. IL-1β levels showed no significant change.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 310.45
分子式 C16H26N2O2S
CAS No. 959746-77-1

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween-80+45% Saline: 0.5 mg/mL (1.61 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 12 mg/mL (38.65 mM; 超声加热助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.2211 mL16.1057 mL32.2113 mL80.5283 mL
5 mM0.6442 mL3.2211 mL6.4423 mL16.1057 mL
10 mM0.3221 mL1.6106 mL3.2211 mL8.0528 mL
15 mM0.2147 mL1.0737 mL2.1474 mL5.3686 mL
20 mM0.1611 mL0.8053 mL1.6106 mL4.0264 mL
25 mM0.1288 mL0.6442 mL1.2885 mL3.2211 mL
30 mM0.1074 mL0.5369 mL1.0737 mL2.6843 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础